This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2.
Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug
by Arpita Dutt
Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.
Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.
Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.
Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.
Celgene (CELG) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Celgene Corporation (CELG) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.
What's in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.
What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?
by Zacks Equity Research
GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.
Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?
by Zacks Equity Research
We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.
Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.
Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.
Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback
by Arpita Dutt
Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.
Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the FDA approved additional indications for Harvoni tablets and Sovaldi tablets.
KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
KMG Chemicals, Gilead Sciences, STMicroelectronics NV, Lockheed Martin and AeroVironment highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Gilead Sciences (GILD)
by Kevin Cook
Could a transformational M&A deal reverse the 18-month slide in sales and profits?
Biotech Stock Roundup: Acorda Down on Court Ruling, Patent Challenge for CELG Drug
by Arpita Dutt
Court rulings and patent challenges made headlines in the biotech sector with companies like Acorda (ACOR) and Celgene (CELG) providing updates.
Gilead (GILD) Up 4.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Galapagos Initiates 3 Phase II Studies for Filgotinib
by Zacks Equity Research
Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.
New Strong Sell Stocks for March 31st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study
by Arpita Dutt
Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
by Arpita Dutt
Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.
Mylan Receives Tentative Approval from FDA for HIV Therapy
by Zacks Equity Research
Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).
Biotech Bull Making a Comeback
by Kevin Cook
A triple-bottom at $240 was bolstered by the headline capitulation of an infamous Valeant investor
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
by Arpita Dutt
Gilead's (GILD) valuation looks compelling but is the company really poised for